| DC66464 |
3BP-3940
Featured
|
3BP-3940 is a highly potent FAP-targeting peptide with significant potential in theranostics. Its ability to be coupled with diagnostic and therapeutic radionuclides makes it a versatile tool for tumor imaging, targeted therapy, and treatment monitoring. By focusing on the tumor stroma, 3BP-3940 offers a promising approach to improving cancer diagnosis and treatment, particularly for cancers with prominent stromal involvement. As research progresses, 3BP-3940 could play a key role in advancing precision oncology. |
|
| DC66465 |
Pentanedioate
Featured
|
Pentanedioate is a valuable starting material for the synthesis of PSMA inhibitors due to its flexible structure and functional groups that mimic natural PSMA ligands. By leveraging its chemical properties, researchers can develop potent and selective PSMA-targeting agents for diagnostic imaging, targeted therapy, and theranostic applications in prostate cancer and other PSMA-expressing malignancies. Its role in drug discovery highlights the importance of simple organic molecules in the development of advanced cancer therapies. |
|
| DC66467 |
F-PSMA 1007
Featured
|
|
|
| DC66468 |
NOTA-octreotide
Featured
|
NOTA-octreotide is a ligand for making [18F]AlF-NOTA-octreotide, which is a PET/CT imaging agent for somatostatin receptor imaging in neuroendocrine tumor patients |
|
| DC66469 |
DOTA-NOC
Featured
|
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging. |
|
| DC66470 |
KN-93 phosphate
Featured
|
KN-93 phosphate is a novel membrane-permeant synthetic inhibitor of purified neuronal CaMK-II, with Ki of 370 nM. |
|
| DC66471 |
4-chloro-1-benzothiophene-2-carboxylic acid
Featured
|
|
|
| DC66472 |
6-bromo-1,2-dimethyl-1H-benzo[d]imidazole
Featured
|
|
|
| DC66473 |
SI-80
Featured
|
|
|
| DC66474 |
Benzobthien-2-yl Ketone (Zileuton Impurity)
Featured
|
|
|
| DC66475 |
2-Chloro-5-(methylthio)pyrimidine
Featured
|
|
|
| DC66476 |
Clevidipine Impurity 21
Featured
|
|
|
| DC66477 |
5,6,7,8-TETRAHYDRO-4 H-CYCLOHEPTA[ D ]ISOXAZOLE-3-CARBOXYLIC ACID
Featured
|
|
|
| DC66478 |
WAY-312778
Featured
|
altering the lifespan of a eukaryotic organism |
|
| DC66479 |
WAY-661957
Featured
|
Androgen Receptor modulator |
|
| DC66480 |
XL413
Featured
|
XL413 is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM. |
|
| DC66481 |
6'-Bromo-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione
Featured
|
|
|
| DC66482 |
CK2α-IN-1
Featured
|
CK2α-IN-1 (compound 2) is a selective CK2α inhibitor (IC50=7.0 µM; Ki=1.6 µM) that exhibits a non-ATP-competitive mode of action. CK2α-IN-1 exhibits good potential for anticancer studies. |
|
| DC66483 |
2,3-Bis(2,6-diisopropylphenylimino)butane
Featured
|
|
|
| DC66484 |
2',4'-Dihydroxy-2-benzoylbenzoic Acid
Featured
|
|
|
| DC66485 |
1,8-Bis(tetramethylguanidino)naphthalene
Featured
|
|
|
| DC66486 |
MCLA hydrochloride
Featured
|
MCLA hydrochloride is a chemiluminescent reagent which can be used to quantify aqueous concentrations of superoxide. |
|
| DC66487 |
GSK-3β inhibitor 12
Featured
|
GSK-3β inhibitor 12 (compound 15) is an inhibitor of GSK-3β. GSK-3β inhibitor 12 inhibits 49.11% and 37.11% activity of 25 μM and 50 μM GSK-3β, respectively. GSK-3β inhibitor 12 can be used for the research of neurodegenerative diseases. |
|
| DC66488 |
CLK1-IN-4
Featured
|
CLK1-IN-4 (Compound 79) is an inhibitor for CDC like kinase 1 (CLK-1) with IC50 of 1.5-2 μM. |
|
| DC66489 |
CB1 agonist 1
Featured
|
CB1 agonist 1 (compound 22) is an agonist of CB1. CB1 agonist 1 shows affinity to CB1 receptor with an pIC50 value of 5.7. CB1 agonist 1 can be used for the research of brain disorders. |
|
| DC66490 |
CK2-IN-4
Featured
|
CK2-IN-4 (compound 5) is a protein kinase (CK2) inhibitor (IC50=8.6 µM). CK2-IN-4 has good potential for research in the areas of cancer, viral infections and glomerulonephritis. |
|
| DC66491 |
BCR-ABL-IN-7
Featured
|
|
|
| DC66492 |
Tyrosine kinase-IN-7
Featured
|
Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC50s for inhibiting EGFR(WT) and EGFR(T790M) are 0.630 μM and 0.956 μM respectively. Tyrosine kinase-IN-7 has antitumor activity against four cancer cell lines (HepG2, HCT-116, MCF-7, and A431) with IC50s of 13.02 μM, 10.14 μM, 12.68 μM, and 47.05 μM, respectively. |
|
| DC66493 |
JY-2
Featured
|
JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity. |
|
| DC66494 |
Casein kinase 1δ-IN-14
Featured
|
Casein kinase 1δ-IN-14 (compound 481) is a casein kinase inhibitor that can be used to study neurodegenerative diseases such as Alzheimer's disease. |
|
